H.R. 1518

119th CongressIn committee

New Era of Preventing End-Stage Kidney Disease Act

New Era of Preventing End-Stage Kidney Disease Act

Sponsored by Gus M. Bilirakis (Republican-FL-12)

Healthcare Costs & Access Healthcare & Public Health Medicare & Medicaid

Cosponsors

56

Actions

3

Roll calls

0

Amendments

0

Related bills

0

Actions

Feb 24, 2025 · Library of Congress

Introduced in House

Feb 24, 2025 · Library of Congress

Introduced in House

Feb 24, 2025 · House floor actions

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest activity

Activity

July 2026

Lobbying reported · Alston & Bird · Jul 20

Alston & Bird reported 2nd Quarter (Apr 1 - June 30) lobbying for Travere Therapeutics — $70,000

BillsH.R. 1414 H.R. 1518

Lobbying reported · American Kidney Fund · Jul 20

American Kidney Fund reported 2nd Quarter (Apr 1 - June 30) lobbying for American Kidney Fund — $240,000

BillsH.R. 1518 H.R. 2199 H.R. 4582 H.R. 4583 H.R. 5259 H.R. 6214 H.R. 6280 H.R. 7868 H.R. 8875 S. 1552 S. 2730 S. 2751 S. 3607

Lobbying reported · Travere Therapeutics · Jul 20

Travere Therapeutics reported 2nd Quarter (Apr 1 - June 30) lobbying for Travere Therapeutics — $140,000

BillsH.R. 1 H.R. 1262 H.R. 1414 H.R. 1518 H.R. 4709 H.R. 9102 S. 932 S. 1040 S. 2658

Lobbying reported · Tiber Creek Group · Jul 18

Tiber Creek Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Vertex Pharmaceuticals — $60,000

BillsH.R. 1227 H.R. 1518 S. 475

Lobbying reported · American Society of Nephrology · Jul 16

American Society of Nephrology reported 2nd Quarter (Apr 1 - June 30) lobbying for American Society of Nephrology — $60,000

BillsH.R. 1518 H.R. 4582 H.R. 4583 H.R. 7581 H.R. 7868 H.R. 7905 H.R. 7961 H.R. 8163 H.R. 8319 H.R. 8367 H.R. 8875 H.R. 9169 H.R. 9509 S. 1552 S. 4070

Lobbying reported · Vertex Pharmaceuticals · Jul 16

Vertex Pharmaceuticals reported 2nd Quarter (Apr 1 - June 30) lobbying for Vertex Pharmaceuticals — $1,200,000

BillsH.R. 1227 H.R. 1414 H.R. 1518 H.R. 6423 S. 475 S. 864

Lobbying reported · Otsuka America Pharmaceutical · Jul 16

Otsuka America Pharmaceutical reported 2nd Quarter (Apr 1 - June 30) lobbying for Otsuka America Pharmaceutical — $1,240,000

BillsH.R. 1518 H.R. 5509 S. 2903

You’re all caught up.